Originally Posted by
Aimless
It's a little more complicated than that, and the difference is easier to understand when you compare the vaccines. Thrombotic/thromboembolic events have been reported after being administered Comirnaty, but the people who have received Comirnaty are almost all very old and have multiple illnesses, which make such events more likely. That is why there hasn't been much alarm over reports of clots after vaccination with Comirnaty. The Norwegian cases, in contrast, have been among people under 50, who are, in general, much less likely to experience such events. Some people are more likely than others to get different kinds of clots even at younger ages, eg. because they have a genetic predisposition—the frequency of which can vary between populations—and it's possible the cases reported occurred among such people. It's also possible they are/were ill in some other way that predisposes them to form dangerous clots. It could also genuinely be a fluke. But the decision to halt the rollout of AZN's vaccine wasn't made in a frivolous manner. Norway's covid situation is also very different from eg. that of England, with barely 3 new hospital admissions per million per day; it's not surprising that they have weighed the risks differently.